Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis.[ Read More ]
The intrinsic value of one ASRT stock under the base case scenario is HIDDEN Compared to the current market price of 0.811 USD, Assertio Holdings, Inc. is HIDDEN
Current Assets | 171 M |
Cash & Short-Term Investments | 73.4 M |
Receivables | 47.7 M |
Other Current Assets | 50 M |
Non-Current Assets | 115 M |
Long-Term Investments | 0 |
PP&E | 2.04 M |
Other Non-Current Assets | 113 M |
Current Liabilities | 93.4 M |
Accounts Payable | 13.4 M |
Short-Term Debt | 928 K |
Other Current Liabilities | 79.1 M |
Non-Current Liabilities | 55 M |
Long-Term Debt | 40 M |
Other Non-Current Liabilities | 15 M |
Revenue | 152 M |
Cost Of Revenue | 27 M |
Gross Profit | 125 M |
Operating Expenses | 369 M |
Operating Income | -244 M |
Other Expenses | 88.4 M |
Net Income | -332 M |
Net Income | -332 M |
Depreciation & Amortization | 28.2 M |
Capital Expenditures | -628 K |
Stock-Based Compensation | 9.16 M |
Change in Working Capital | 140 K |
Others | 254 M |
Free Cash Flow | 49 M |
Date | Value | Insider | Amount | Avg Price |
---|---|---|---|---|
3 days ago
Nov 14, 2024
|
Bought 9.95 K USD
|
O'Grady Brendan P.
CEO |
+ 11706.462
|
0.85 USD |
5 months ago
Jun 11, 2024
|
Bought 11.1 K USD
|
Vacirca Jeff L
Director |
+ 10000
|
1.11 USD |
5 months ago
Jun 05, 2024
|
Bought 24.2 K USD
|
Mason Heather L
Interim Executive Officer |
+ 25000
|
0.97 USD |
8 months ago
Mar 14, 2024
|
Sell 11.5 K USD
|
Tyree James L
Director |
- 10251
|
1.1182 USD |
1 year ago
Sep 11, 2023
|
Sell 137 K USD
|
Schlessinger Sam
SVP, General Counsel |
- 45236
|
3.0383 USD |
1 year ago
Sep 11, 2023
|
Sell 196 K USD
|
Patel Ajay
SVP and CAO |
- 64313
|
3.0444 USD |
1 year ago
Sep 11, 2023
|
Sell 323 K USD
|
Schwichtenberg Paul
SVP and CFO |
- 104980
|
3.0729 USD |
1 year ago
Sep 11, 2023
|
Sell 387 K USD
|
Peisert Daniel A.
President & CEO |
- 127281
|
3.0403 USD |
1 year ago
Sep 12, 2023
|
Sell 92.4 K USD
|
Peisert Daniel A.
President & CEO |
- 31121
|
2.9701 USD |
1 year ago
Aug 14, 2023
|
Sell 69 K USD
|
MCKEE WILLIAM
Director |
- 22000
|
3.1384 USD |
1 year ago
May 19, 2023
|
Sell 652 K USD
|
Mason Heather L
Director |
- 89286
|
7.3025 USD |
1 year ago
May 05, 2023
|
Sell 259 K USD
|
Tyree James L
Director |
- 43143
|
5.9979 USD |
2 years ago
May 12, 2022
|
Sell 105 K USD
|
Tyree James L
director: |
- 44643
|
2.3558 USD |
2 years ago
May 12, 2022
|
Sell 52.5 K USD
|
MCKEE WILLIAM
director: |
- 22322
|
2.3514 USD |
2 years ago
Apr 11, 2022
|
Sell 92.4 K USD
|
Peisert Daniel A.
President and CEO |
- 26391
|
3.5 USD |
2 years ago
Apr 05, 2022
|
Sell 121 K USD
|
Peisert Daniel A.
President and CEO |
- 34518
|
3.5 USD |
3 years ago
May 20, 2021
|
Bought 14.8 K USD
|
Schwichtenberg Paul
SVP and CFO |
+ 9750
|
1.514 USD |
3 years ago
May 20, 2021
|
Bought 24.5 K USD
|
Peisert Daniel A.
President and CEO |
+ 15909
|
1.54 USD |
3 years ago
May 20, 2021
|
Bought 12.5 K USD
|
Patel Ajay
SVP and CAO |
+ 8169.934
|
1.53 USD |
3 years ago
Dec 23, 2020
|
Sell 2.54 M USD
|
CR Group L.P.
10 percent owner |
- 6784334
|
0.3745 USD |
3 years ago
Dec 24, 2020
|
Sell 730 K USD
|
CR Group L.P.
10 percent owner |
- 1982851
|
0.3682 USD |
3 years ago
Dec 18, 2020
|
Sell 189 K USD
|
CR Group L.P.
10 percent owner |
- 500000
|
0.3776 USD |
3 years ago
Dec 21, 2020
|
Sell 180 K USD
|
CR Group L.P.
10 percent owner |
- 500000
|
0.3602 USD |
3 years ago
Dec 22, 2020
|
Sell 509 K USD
|
CR Group L.P.
10 percent owner |
- 1500000
|
0.339 USD |
4 years ago
May 08, 2020
|
Sell 12.5 K USD
|
DAWES KAREN A
Director |
- 15834
|
0.7914 USD |
5 years ago
Nov 11, 2019
|
Bought 9.91 K USD
|
STAPLE PETER D
Director |
+ 13900
|
0.713 USD |
5 years ago
Nov 12, 2019
|
Bought 18.2 K USD
|
HIGGINS ARTHUR J
Director, President and CEO |
+ 25000
|
0.73 USD |
5 years ago
Aug 19, 2019
|
Bought 40.2 K USD
|
HIGGINS ARTHUR J
Director, President and CEO |
+ 25000
|
1.6097 USD |
5 years ago
Aug 13, 2019
|
Bought 6.23 K USD
|
Bukofzer Stan
SVP, Chf Scitfc & Tech Officer |
+ 4000
|
1.557 USD |
5 years ago
Aug 12, 2019
|
Bought 76.9 K USD
|
HIGGINS ARTHUR J
Director, President and CEO |
+ 50000
|
1.538 USD |
5 years ago
Jun 13, 2019
|
Sell 39.8 K USD
|
DAWES KAREN A
Director |
- 12500
|
3.1835 USD |
5 years ago
Mar 14, 2019
|
Bought 41.7 K USD
|
HIGGINS ARTHUR J
Director, President and CEO |
+ 10000
|
4.17 USD |
5 years ago
Mar 14, 2019
|
Bought 20.7 K USD
|
Bukofzer Stan
SVP, Chf Scitfc & Tech Officer |
+ 5000
|
4.1315 USD |
5 years ago
Dec 03, 2018
|
Sell 40.7 K USD
|
DAWES KAREN A
Director |
- 8421
|
4.8361 USD |